USP47 and chronic myelogenous leukemia, BCR-ABL1 positive: In summary, we demonstrate that USP47 is a target for CML treatment and targeting USP47 is a promising strategy for overcoming TKI resistance and eradicating leukemia stem/progenitor cells in CML.